What's driving patients' placebo effect?

Drug developers are well-versed in the potential pitfalls posed by placebos. The dread "placebo effect" has done in  more than a few experimental drugs which couldn't compete against the sudden response seen in patients who were given a sugar pill. Now investigators are exploring why so many people respond to a placebo--even when they know it isn't a therapy. "Right now, I think evidence is that placebo changes not the underlying biology of an illness, but the way a person experiences or reacts to an illness," Dr. Ted Kaptchuk, director of Harvard's Program in Placebo Studies and the Therapeutic Encounter, tells The Wall Street Journal. Story

Suggested Articles

German researchers uncovered 28 antibodies that neutralize COVID-19 and are working with Boehringer Ingelheim to advance them into clinical testing.

Oragenics is ending a phase 2 study of its oral mucositis drug, yanking its IND application and switching its focus to a COVID-19 vaccine.

The vehicle, which Blackstone claims is the largest life sciences private fund, has committed close to $1 billion to companies including Alnylam.